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Abstract
Stimuli-responsive anticancer formulations can promote drug release and activation within the
target tumour, facilitate cellular uptake, as well as improve the therapeutic efﬁcacy of drugs and
reduce off-target effects. In the present work, indocyanine green (ICG)-containing polyglutamate
(PGA) nanoparticles were developed and characterized. Digestion of nanoparticles with
cathepsin B, a matrix metalloproteinase overexpressed in the microenvironment of advanced
tumours, decreased particle size and increased ICG cellular uptake. Incorporation of ICG in PGA
nanoparticles provided the NIR-absorbing agent with time-dependent altered optical properties
in the presence of cathepsin B. Having minimal dark toxicity, the formulation exhibited
signiﬁcant cytotoxicity upon NIR exposure. Combined use of the formulation with saporin, a
ribosome-inactivating protein, resulted in synergistically enhanced cytotoxicity attributed to the
photo-induced release of saporin from endo/lysosomes. The results suggest that this therapeutic
approach can offer signiﬁcant therapeutic beneﬁt in the treatment of superﬁcial malignancies,
such as head and neck tumours.
S Online supplementary data available from stacks.iop.org/NANO/28/055101/mmedia
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1. Introduction
Nanotechnology has signiﬁcantly contributed in improving
drug bioavailability and therapeutic index in cancer therapy.
Nanoparticulate formulations have been developed that, apart
from serving as drug carriers, have the attribute to respond to
endogenous, disease-associated stimuli or externally applied
stimuli [1]. Responsiveness to these stimuli can offer spa-
tiotemporal treatment control by promoting site-speciﬁc
accumulation, drug release and/or activation in or around
target lesions.
In cancer, disease-speciﬁc stimulation can be provoked
by the well-known distinctive characteristics of the tumour
microenvironment, such as the acidic pH [2], the enhanced
permeability and retention (EPR) effect [3], the abundance of
proteolytic enzymes [4], hypoxia [5] and the overexpression
of particular cell membrane receptors [6]. Among these, the
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EPR effect involves atypical and leaky vasculature, as well as
poor lymphatic drainage that promote nanoparticle accumu-
lation and retention in tumours [3]. The tumour micro-
environment also contains upregulated proteolytic enzymes,
such as matrix metalloproteinases, that are required for cancer
progression. These endogenous tumour-speciﬁc character-
istics provide valuable tools for the design of formulations
that will only be activated in the tumour microenvironment.
Polyglutamate (PGA) is among the biodegradable polymeric
molecules that have been successfully used in drug delivery
systems for cancer, mainly as PGA-drug conjugates. PGA can
be digested by cathepsin B, which is a lysosomal protease in
normal cells and tissues [7]. In malignant tumours, the
expression of cathepsin B is highly upregulated and the
enzyme is secreted into the extracellular environment [8]. The
concept of using PGA as a carrier for anticancer agents is
based on the observation that drugs appear to be inactive
while bound onto PGA chains and they elicit their cytotoxic
action once the polymer backbone is digested within the
tumour microenvironment [9]. PGA-based formulations have
been developed that have signiﬁcantly enhanced the efﬁcacy
of agents, such as camptothecin and paclitaxel, not only by
promoting tumour-speciﬁc cytotoxicity but also by improving
their solubility in blood following systemic administration
[1, 10]. For instance, clinical studies on paclitaxel poly-
glumex, a PGA-paclitaxel conjugate, have demonstrated that
this drug formulation is preferentially trapped in the tumour
microenvironment allowing the tumour to be exposed to
signiﬁcantly higher chemotherapeutic concentrations than
those in off-target tissues [7, 9, 11].
Externally-applied stimuli that can be employed in drug
delivery and drug activation for cancer include light, ultra-
sound, magnetic ﬁelds and heat. Among these, light has been
successfully employed as a stimulus for the locoregional
ablation of superﬁcial lesions, such as skin, as well as head
and neck cancers. Apart from laser-induced interstitial ther-
motherapy that uses light as the sole heat-producing source,
laser light is often used with light-sensitive drugs, known as
photosensitizers, to kill cancer cells in a treatment known as
photodynamic therapy (PDT) [12]. In PDT, light in combi-
nation with a photosensitizer, triggers the production of
cytotoxic reactive oxygen species that lead to the non-thermal
ablation of lesions. It has been shown that amphiphilic pho-
tosensitizers can be integrated in the cytoplasmic membrane,
subsequently translocate to the endo/lysosomal membranes
so that the latter become light-sensitive [13]. Sensitization of
the latter can result in the release of components that are
compartmentalized in endocytic vesicles when exposed to
light. This treatment modality, known as photochemical
internalization (PCI), is a novel technology for release of
endocytosed agents, such as ribosome-inactivating proteins,
therapeutic nucleic acid or bleomycin, into the cytosol prior to
their deactivation by lysosomal enzymes [14]. A photo-
thermal approach has also been developed for triggering
cytosolic release of agents via endosome disruption, in a
similar manner as PCI. The photothermally-triggered cyto-
solic drug delivery approach involved the inclusion of agents
that absorb light for the production of heat, which can induce
endo/lysosomal disruption and subsequently enhance che-
motherapy [15, 16]. Among the photoresponsive agents used
for the light-based therapeutic modalities described above,
those that absorb light in the near-infrared (NIR) region of the
electromagnetic spectrum have received considerable atten-
tion. The advantage of using NIR light (650–900 nm wave-
length) in treatment is that it provides deeper tissue
penetration when compared with light of lower wavelengths
[17]. In addition, the presence of an NIR-absorbing agent
within the tumour mass can lower the threshold of the energy
required to achieve an ablative effect locally [18].
Indocyanine green (ICG) is a NIR-absorbing dye
approved by the US FDA and has been used clinically as a
diagnostic agent in angiography. More recently, the use of
ICG for tumour imaging, hyperthemic cancer ablation and
laser-induced drug release has gained increasing attention.
When exposed to NIR laser light, ICG can convert the
absorbed energy into heat due to internal conversion [19].
This results in local hyperthermia with subsequent ablative
effects in tumours [20]. Moreover, a number of studies have
demonstrated the non-hyperthemic cytotoxic effects of ICG
under NIR irradiation. These effects include the photo- and
sonosensitizing activity of ICG, as well as the induction of
PCI of chemotherapeutic agents on the basis of the amphi-
philic nature of the molecule. In our own studies, we have
demonstrated the cytotoxic and antitumour effect of intratu-
morally-injected ICG, in combination with laser light and
low-intensity ultrasound [21]. The photo- and sonosensitizing
effects of ICG, triggered by light and ultrasound irradiation,
have been attributed to mitochondrial destruction that leads to
the build-up of intracellular cytotoxic free radicals and sub-
sequent cell death.
A number of different aspects limit the applicability of
ICG in laser-based cancer ablation. This limitation has been
attributed to the instability of ICG in aqueous solutions and
the high afﬁnity of this molecule for plasma proteins after
intravenous injection, followed by rapid hepatic elimination
from blood circulation [22]. These characteristics result in
poor biodistribution of this agent after systemic administra-
tion and a very short half-life of only about 2–4 min [23].
Efforts have been made to overcome these limitations mainly
by physical encapsulation of ICG into delivery systems for
improving the efﬁcacy of this agent in cancer imaging and
therapy [20, 24, 25].
In this study, we describe novel PGA-based nanoparticles
carrying ICG for NIR-based treatment of head and neck
cancers. The nanoparticulate formulation developed herein is
intended to improve the optical properties of ICG for systemic
administration, improve tumour accumulation and facilitate
improved cellular uptake of the light-responsive agent. The
use of the formulation to elicit stimulus-responsive cytotoxic
effects and also to improve cellular uptake of saporin, a
ribosome-inactivating protein, upon NIR irradiation is eval-
uated using an in vitro target.
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2. Methods
2.1. Cell culture
SCC-9, a human squamous carcinoma of the tongue cell line,
was obtained from Sigma, UK. The cell line was maintained
in DMEM/Ham’s F-12 tissue culture medium supplemented
with 2 mM glutamine (GibcoBRL,UK), 0.5 mM sodium
pyruvate, 10% v/v fetal bovine serum (Life Technologies,
UK) and 0.2 μg hydrocortisone (Sigma, UK) at 37 °C in a 5%
CO2 humidiﬁed atmosphere. When required, single cell sus-
pensions were prepared by treating cell monolayers with a
0.05% w/v solution of trypsin containing 0.02% w/v EDTA
in phosphate-buffered saline (PBS).
2.2. PGA digestion with cathepsin-B
PGA (0.1 mg ml−1) was incubated with cathepsin B (from
human placenta; Sigma-Aldrich, UK) (0.6 units ml−1) in PBS
for 3 days, in an orbital incubator, at 37 °C. 10 μl aliquots
were obtained from the incubating mixture every 24 h.
Samples were stored at −20 °C and were treated with redu-
cing SDS loading buffer prior to gradient SDS/PAGE. Fol-
lowing electrophoresis, gels were stained with coomassie blue
for 24 h for exposing the ladder bands and subsequently, with
alcian blue (BDH Chemicals, UK) for visualizing PGA [26].
2.3. Preparation of ICG-PGA nanoparticles
Nanoparticles were prepared using a modiﬁcation of the
protocol suggested by Zia et al [27]. Brieﬂy, 5 mg of poly-l-
glutamic acid sodium salt (PGA) (MW: 50–100 kDa; Sigma-
Aldrich, UK) and 5 mg of ICG (Sigma Aldrich, UK) were
dissolved in 10 ml of dimethyl sulfoxide (DMSO). This was
added drop-wise to a poly(vinyl alcohol) solution (10 mg in
5 ml H2O) (MW: 30–70 kDa; Sigma-Aldrich, UK) under
constant stirring. The resulting mixture was stirred at room
temperature for 1 h and was then dialysed (MWCO: 8 kDa)
against deionised water, for 24 h. The dialysed suspension
was centrifuged at 38 000 g for 1 h using a Beckman Opti-
maTM L-80 Ultracentrifuge. The pellet was washed twice
with deionised water and was then suspended in 2 ml of
water. The precipitated nanoparticles were then probe-soni-
cated for 3 min, followed by further dialysis against water, for
12 h, to remove any free ICG. The dialysed solution was then
ﬁltered using a micro syringe ﬁlter (0.22 μm). The suspension
was snap-frozen and freeze dried for 48 h.
2.4. Nanoparticle characterization and the effect of digestion
with cathepsin B
The methods employed to characterize the nanoparticles in
terms of size, surface charge and morphology are described in
detail in the supplementary material. In order to determine the
effect of cathepsin B on nanoparticle degradation, an enzy-
matic digestion assay was set up followed by size-exclusion
ﬁltration through a MWCO 300 kDa membrane (supple-
mentary material).
For time-depended absorbance and ﬂuorescence emission
characterization, PBS solutions/suspensions (pH 7.4) con-
taining free ICG, or ICG nanoparticles in the absence
(ICGNP) or the presence (d.ICGNP) of cathepsin B (0.6 units
ml−1) were stored in an orbital incubator at 37 °C, protected
from light, for 3 days. The equivalent ICG concentration in all
systems was 6 μg ml (7.8 μM). Absorption and ﬂuorescence
emission spectra of these systems were acquired at pre-
determined times. The excitation wavelength of 740 nm was
used to obtain the ﬂuorescence spectra. For the afore-men-
tioned experiments, spectra and ﬂuorescence intensities were
obtained using a CLARIOstar® High Performance Mono-
chromator Multimode microplate reader (BMG LAB-
TECH, UK).
2.5. Cellular uptake of nanoparticles
In order to study the cellular uptake of the ICG-containing
formulation and the effect of cathepsin B digestion on uptake,
SCC-9 cells were added to individual wells of 96-well plates
at a concentration of 9×103 cells/well. 24 h later, each ICG
formulation (free ICG, ICGNP, d.ICGNP) was added in
serum-containing growth medium in each well at a ﬁnal ICG
concentration of 3 μM. The effect of saporin on nanoparticle
cellular uptake was also examined. Saporin was added at a
ﬁnal concentration of 40 nM. All systems were incubated at
37 °C in a 5% CO2 humidiﬁed atmosphere for 24 h. The
growth medium was removed and cell monolayers were
washed with medium. 50 μl of DAPI solution (300 nM) was
added to each well and plates were examined using the
microplate reader. Further details on the experimental set-up
are provided in the supplementary material.
2.6. NIR-laser treatment of cells
In order to examine the effect of laser light on cells treated
with ICG nanoparticles, saporin, or the combination thereof,
SCC-9 cells were seeded in 96-well plates at a concentration
of 9×103 cells/well. After 24 h, saporin and/or each ICG-
containing formulation (free ICG, ICGNP, d.ICGNP) were
added to the serum-containing growth medium in each well at
a ﬁnal ICG concentration of 3 μM. Saporin was added at a
ﬁnal concentration of 40 nM. All systems were incubated at
3 °C in a 5% CO2 humidiﬁed atmosphere for 24 h. The
medium was removed, and cell monolayers were washed and
reﬁlled with fresh medium. Systems were irradiated with
light, through a CUT-END Model OTO00 optical ﬁbre
(Medlight, Switzerland), at 805 nm and 150 mW cm−2, for
5 min (45 J cm−2 total energy), using a BIOMED 25 (Biomed
Ltd, UK) laser. Treatments we performed at room temperature
(22 °C). The actual irradiating power density that the target
samples were exposed to (150W cm−2) was calibrated each
time using a Gentec TPM-300 laser power metre. Treated
cells were further incubated for 24 h, before examination of
cell viability using a bioluminescence-based assay. The
thermal effects of NIR laser irradiation in the cell treatment
was measured with a thermocouple. The photo-induced agent
internalization with rhodamine-dextran as a surrogate for
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saporin was examined using microscopy. These methods are
described in detail in the supplementary material.
2.7. Statistical analysis
Results are shown as mean or mean±standard deviation.
Unless otherwise stated, two-way ANOVA with Bonferroni
post-test was performed to evaluate signiﬁcance among
multiple groups in GraphPad Prism version 5.01. Herein, a
single asterisk (*) indicates P<0.05, double asterisk (**)
indicates P<0.01 and triple asterisk (***) indicates
P<0.001.
3. Results and discussion
3.1. PGA digestion with cathepsin-B
PGA is a polypeptide that is cleaved by cathepsin B over-
expressed in the tumour microenvironment and this
phenomenon has previously been used for improving the
tumour uptake of agents in clinically available formulations.
In order to assess the effect of cathepsin B on PGA, the latter
was incubated in the presence or the absence of the proteo-
lytic enzyme at 37 °C over the course of 3 days. Samples
acquired every 24 h were subjected to gel electrophoresis and
the image of the resolving gel is shown in ﬁgure 1. PGA
samples incubated in the absence of cathepsin B showed a
smear-like band extending from the highest (170 kDa) to the
lowest (35 kDa) molecular weights. The proﬁle of the smear-
like band, in terms of breadth and intensity remained
unchanged even after incubation for 3 days in the absence of
cathepsin B. However, in the presence of cathepsin B, the
smear-like band became less intense with digestion time and
shifted towards lower molecular weights. In addition to ver-
ifying that the PGA remained stable for 3 days in the absence
of cathepsin B, the SDS-PAGE analytical system also proved
useful in verifying that our preparation of PGA was also
sensitive to cathepsin B.
3.2. Nanoparticle characterization and the effect of digestion
with cathepsin B
For the preparation of the PGA-based nanoparticles contain-
ing ICG a self-assembly method was employed and this
resulted in an encapsulation efﬁciency of 8±1.60% (n=3).
The mean hydrodynamic diameter of the undigested nano-
particles as determined using DLS was 113±1.78 nm
(n=3) and images from scanning electron microscopy
(SEM) showed nanoparticles with globular morphology
(ﬁgure 2(a)). The surface potential of the particles was
−7±1.3 mV (n=3). Enzymatic digestion of the nano-
particles with cathepsin B for 3 days resulted in measurable
globular particles with mean hydrodynamic diameter
56±1.22 nm (n=3), which shows a 50% decrease in
average size. The digestion-induced decrease in size was
further conﬁrmed with SEM analysis (ﬁgure 2(b)). Enzymatic
digestion also results in smaller structures in the form of PGA
complexes with ICG or free ICG (ﬁgure 3(a)), as conﬁrmed
by results from the experiments using size-exclusion ﬁltration
(ﬁgure 3(b)). Here ICG-containing nanoparticles were
digested with cathepsin B and both these and undigested
samples were subjected to size exclusion ﬁltration using a
300 kDa cut-off membrane. Filtrates were examined using
ﬂuorescence spectroscopy for ICG and those from the
digested formulation showed a 48% increase in ﬂuorescence
(p=0.002, independent t-test) when compared with the
undigested sample (ﬁgure 3(b)). The latter demonstrates that,
apart from nanoparticle size reduction detected by DLS,
cathepsin B digestion results in the formation of smaller ICG-
PGA complexes and/or free ICG (ﬁgure 3(a)).
In order to more fully characterize the optical properties
of the nanoparticles optical proﬁles of free ICG, ICG nano-
particles (ICGNP) and ICG nanoparticles in the presence of
cathepsin B (d.ICGNP) were compared by examining their
absorbance and ﬂuorescence spectra in PBS solutions/sus-
pensions over a period of 4 days. Figure 4 displays the
absorbance (ﬁgure 4(a)) and ﬂuorescence (ﬁgure 4(b)) spectra
of free ICG, ICGNP and d.ICGNP, incubated at 37 °C, over
the course of 4 days. Initially (Day 0), the sample of free ICG
showed the characteristic ICG absorbance proﬁle in PBS with
peak maximum at 774 nm. The absorption proﬁle of the
nanoparticulate formulation displayed a broad peak, extend-
ing over a wider NIR wavelength range. The broad peak
resolves after 24 h revealing a peak at 774 nm, which suggests
release of free ICG from the nanoparticles. A similar
phenomenon has been observed in previous studies employ-
ing ICG-containing nanoparticulate formulations, such as
liposomes and emulsions [28, 29]. The sharper peak at
774 nm that appeared in the case of the digested sample,
suggests an improved rate of ICG release when compared
with the undigested system. The newly formed peak that
appeared at 888 nm conﬁrmed the complexation of ICG with
PGA to form nanoparticles with a subsequent signiﬁcant red
shift, probably associated with the formation of so called
J-aggregate [30]. The appearance of an absorbance peak at
signiﬁcantly higher wavelengths than that of the free agent
has been observed previously in the case of NIR-absorbing
Figure 1. SDS-PAGE electrophoresis of PGA incubated in the
absence or the presence of cathepsin B (cath B) over 72 h.
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cyanine dyes in complexation with protein molecules [31]. In
that study it was found that the absorbance peak that appeared
at higher wavelengths as a result of the formation of cyanine-
protein complexes was soon replaced by a Soret absorption
band at wavelengths lower than that of the free cyanine. In the
current study, the newly formed peak at 888 nm that corre-
sponds to the absorbance of the ICG nanoparticulate com-
plexes with PGA was sustained even after the absorbance of
the free ICG declined over the period of 4 days. In addition,
no blue shift in the absorbance spectra of the formulation was
observed over time. The attribute of the formulation to absorb
lower energy light than the free agent will be the subject of
further investigations and it could offer potential for the
treatment of deeper lesions. The absorbance spectra in
ﬁgure 4(a) also conﬁrmed a considerable difference in stabi-
lity between the free ICG and the ICG incorporated in
nanoparticles. The maximum absorbance at 888 nm after 24 h
decreased in a time-dependent manner at 37 °C either due to
release of ICG and subsequent destabilization of the agent in
aqueous solution or due to slow destabilization of the agent
within the nanoparticles. Degradation of ICG in aqueous
media is caused by saturation of the double bonds in the
conjugated molecule, with subsequent decrease of both the
absorbance and ﬂuorescence [32]. A number of studies have
reported the development of ICG-carrying nanoparticulate
formulations for improving ICG stability at 37 °C in aqueous
media. A study by Yan & Qiu demonstrated that incorpora-
tion of ICG in the hydrophobic environment of polymeric
micelles provided the molecule with chemical stability over a
period of 10 d [20]. Although the hydrophilic nature of the
formulation described in the current study did not provide the
level of ICG stability reported in previous studies, from a
practical perspective the spectra demonstrated adequate sta-
bility to allow a 3-day window for repeated treatment if
required in a clinical environment.
Figure 2. Size distribution using DLS and SEM images of the undigested (a) and enzyme-digested (b) nanoparticles.
Figure 3. (a) Schematic illustration of nanoparticle enzymatic digestion, with subsequent formation of smaller particles and release of free
ICG, and (b) ﬂuorescence emission of ﬁltrates from size-exclusion ﬁltration of the undigested (ICGNP) and digested (d.ICGNP)
nanoparticles (n=3).
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Fluorescence spectra showed that incorporation of ICG in
the nanoparticulate formulation resulted in a signiﬁcant sup-
pression of ﬂuorescence emission (74%) (ﬁgure 4(b)). This
phenomenon can be attributed to the nanoparticulate struc-
ture, which offers a different local environment to the bound
ICG molecule when compared with the free form [33]. ICG
molecules that are in close proximity within the nanoparticle
assembly quench each another and this inevitably results in
reduced ﬂuorescence emission [34, 35]. As stated above, the
ﬂuorescence of free ICG gradually decreased overtime and
63% of the ﬂuorescence is lost after 24 h of incubation. In the
case of the system that was incubated in the presence of
cathepsin B, ﬂuorescence increased by 74% after 24 h, and at
that point the intensity of the digested system was 77% higher
than that of the free ICG, while ﬂuorescence of the undigested
nanoparticles remained low. This phenomenon conﬁrms
enzyme-induced nanoparticle degradation and increased ICG
release during incubation, subsequently leading to ﬂuores-
cence recovery. After 3 d incubation, ﬂuorescence emission
of the system under digestion decreased by 25% from day 1;
however, intensity still remained 66% higher than that of
free ICG.
Results on the absorbance and ﬂuorescence emission
proﬁles of the formulation, in comparison to those of free
ICG, suggest that the assembly of the PGA nanoparticulate
structure offers unique optical properties that can be exploited
for improving the therapeutic efﬁcacy of ICG as a tumour-
speciﬁc photo-responsive agent, as well as for reinforcing the
potential of this agent for applications in cancer diagnosis and
imaging. As discussed, ICG is a promising NIR dye for
tumour imaging; however, the poor stability, biodistribution
and lack of targeting limit its application [24]. In this study, a
nanoparticulate system has been designed for carrying ICG
and with the intention of improving the biodistribution,
tumour accumulation and stability proﬁle of this agent.
Moreover, the cathepsin B—induced increase in ﬂuorescence
emission observed at 24 h post-incubation of the nano-
particles demonstrates the potential of this formulation from a
diagnostic perspective for the selective detection and ima-
ging/delineation of highly aggressive tumours with elevated
proteolytic enzyme activity.
3.3. Cellular uptake of nanoparticles
The cellular uptake of the ICG-containing nanoparticles
(ICGNP) was examined and compared to the uptake of the
ICG-containing PGA-nanoparticles that were digested with
cathepsin B for three days (d.ICGNP). Cellular uptake of
these formulations was also compared to that of free ICG, at
the same concentration. In later part of this study, the efﬁcacy
of ICGNP in promoting endo/lysosomal escape of saporin is
examined. For this reason, it was considered necessary to
investigate the effect of saporin on nanoparticle cellular
uptake, for more informative evaluation of the combined
treatment. Results shown in ﬁgure 5(a) demonstrate that the
use of PGA-based nanoparticles signiﬁcantly improved cel-
lular uptake of ICG by 3.2-fold (p<0.001) in comparison to
uptake of free ICG. In addition, uptake was further increased
by 9% (p<0.05) when the nanoparticles were digested with
cathepsin-B. Interestingly, saporin facilitated a 42% increase
in the uptake of ICG using the ICGNP system. This
Figure 4. Time-dependent evolution of the absorbance (a) and ﬂuorescence (b) spectra of free ICG (ICG), nanoparticles (ICGNP) and
nanoparticles in the presence of cathepsin B (d.ICGNP), incubated at 37 °C in the time course of 4 days.
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phenomenon can be explained by the fact that saporin is
highly positively charged [36] and its electrostatic interaction
with the cell membrane may enhance endocytic activity that
concurrently increases cellular uptake of the negatively-
charged nanoparticles. However, the cellular uptake of d.
ICGNP was decreased by 13% (p<0.001) in the presence of
saporin. The latter can be attributed to the high protein afﬁnity
of free ICG released following nanoparticle degradation that
could have inhibited efﬁcient cellular uptake. Nevertheless,
cellular uptake for both ICGNP and d.ICGNP in the presence
of saporin was still signiﬁcantly higher than the uptake using
free ICG (p<0.001).
It has been suggested that nanoparticles with sizes that
are optimal for delivery on the basis of the EPR effect
(20–200 nm) have poor diffusion within solid tumours fol-
lowing extravazation [37, 38]. In addition, smaller particles
(<10 nm), with better tumour diffusion capability [39], are
readily eliminated from blood circulation and show inefﬁcient
EPR-based delivery [40, 41]. The formulation described in
this study has an appropriate size for increasing tumour
accumulation through the EPR effect after administration via
blood circulation. The innovative aspect of this formulation is
that, upon degradation by cathepsin B, smaller particles are
produced, which can potentially diffuse through the mass of
dense tumour tissue more efﬁciently than the formulation that
was initially administered. Moreover, according to the results
in this study, degradation into smaller particles results in
improved cellular uptake, further demonstrating the multi-
dimensional beneﬁt of this system.
MMP-mediated, site-speciﬁc drug delivery based on the
chemical conjugation of drugs to either synthetic polymers or
proteins that are recognized and cleaved by MMPs for release
are currently under development [7, 42–44]. One dis-
advantage of this general approach is that the released drugs
will have a peptide sequence or a residual part thereof
attached, which can potentially compromise the activity of the
drug. The formulation proposed in this study, presents an
alternative approach to form a safe, stable and MMP-clea-
vable carrier, which does not necessitate any chemical mod-
iﬁcation of the payload.
3.4. NIR-laser treatment of cells
In order to examine the photo-induced effect of ICG-carrying
nanoparticles on SCC-9 cells, the latter were treated with
45 J cm−2 total energy using 805 nm laser light following a
24 h incubation with the ICG formulations. The data shown in
ﬁgure 5(b) demonstrate that incubation with free ICG and
ICG-containing nanoparticles, either undigested or digested
with cathepsin B, resulted in minimal toxicity without laser
irradiation. Treatment with laser light resulted in 9%, 37%
and 47% toxicity in the case of free ICG, ICGNP and d.
ICGNP, respectively. These results demonstrate that incor-
poration of ICG in the PGA-based nanoparticles signiﬁcantly
Figure 5. (a) Cellular uptake of ICG, ICGNP and d.ICGNP, in the absence (-Sap) or the presence (+Sap) of saporin. Data groups were
compared using one-way ANOVA with Tukey’s multiple comparison test (MCT) (n=3). (b) Cell viability of SCC-9 cells treated with no
ICG (PBS), ICG, ICGNP and d.ICGNP, under no laser irradiation or under NIR laser irradiation (805 nm, 150 mW cm−2, 5 min) (n=3). (c)
Temperature proﬁles of laser-irradiated DMEM/Ham’s F-12 (medium), ICG-containing medium, ICGNP-containing medium and d.ICGNP
-containing medium (n=3). (d) Cell viability of SCC-9 cells treated with no ICG (PBS), ICG, ICGNP and d.ICGNP in the presence of
saporin (Sap), with no laser irradiation or under NIR laser irradiation (805 nm, 150 mW cm−2, 5 min) (n=3).
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increased the effect of the agent under laser light exposure
and this effect was primarily a result of the improved cellular
uptake of the ICGNP and d.ICGNP formulations (ﬁgure 5(a)).
In the literature, a number of different mechanisms for
the cytotoxic effect of ICG upon NIR irradiation have been
suggested. Although the main mechanism has been described
as a photothermal effect causing heat-mediated cell death,
mechanisms such as the induction of mitochondrial dys-
function and the generation of cytotoxic singlet oxygen,
possibly resulting from highly localized elevated tempera-
tures, have also been suggested to be responsible for the effect
of irradiated ICG on cells [22]. In our study, the ICG-
dependent increase in temperature measured was in the range
of 2 °C for all tested ICG forms (ﬁgure 5(c)). Although a low
ICG-dependent increase in temperature was observed for the
current system upon laser treatment, highly localized thermal
effects at a microscopic level could be possible, particularly
after ICG-nanoparticles from the incubation medium were
concentrated in the subcellular environment (ﬁgure 5(a)).
Previously, both studies by Wan et al [25], for A549 cells,
and by Jian et al [45], for HeLa cells, showed a 25% cytotoxic
effect using ICG-containing micelles, at equivalent ICG
concentrations, upon irradiation with total energy of
270 J cm−2 and 375 J cm−2, respectively. Herein, with sig-
niﬁcantly lower energy provided, the nanoparticles resulted in
a 37% decrease in cell viability and nanoparticle digestion by
cathepsin B contributed to an additional 10% in cell toxicity
upon NIR treatment. Although, differences in the response to
treatment among different cell lines do exist, these results
demonstrate the improved performance of the proposed for-
mulation in potentiating the NIR-triggered effect of ICG for
anticancer therapy.
The tumour microenvironments in different human can-
cers have been extensively characterized, and most of them
share the same characteristics, particularly at their advanced
stages [1]. Speciﬁcally for oral squamous cell carcinoma,
overexpression of cathepsin B has been correlated with car-
cinoma invasion and progression, and the level of expression
of this protease has been studied as a prognostic indicator in
patients with oral cancer [46]. In addition, when the EPR
effect in oral cancer was exploited for NIR ﬂuorescence
optical imaging in preclinical studies, the tumours were
clearly demarcated in vivo and conﬁrmed by histological
analysis to provide tumour-to-background ratios similar to
those delivered using conventional contrast agents [47]. The
afore-mentioned, in combination with their superﬁcial nature,
suggests that oral tumours present a suitable target for the
proposed system.
3.5. Effect of nanoparticles on saporin toxicity
In order to study the effect of NIR-irradiated ICG nano-
particles on saporin toxicity, SCC-9 cells were co-incubated
for 24 h with each ICG formulation and saporin at non-lethal
doses. After washing with agent-free medium, cells were
treated with laser light at the afore-mentioned parameters.
Data shown in ﬁgure 5(d) demonstrate that, without laser
irradiation, saporin had little effect on cell viability both in the
presence and the absence of free ICG (PBS). Following laser
light exposure, the mean cell viability decreased by 4% and
10% in the absence and the presence of free ICG, respec-
tively. In the presence of nanoparticles, saporin toxicity
without light irradiation was 21% and 25% (p>0.05) in the
case of the ICGNP and the d.ICGNP formulation, respec-
tively. This phenomenon could suggest that the PGA-based
nanoparticles interact with saporin and they either enhance
cellular uptake of saporin and/or protect saporin from deac-
tivation resulting from lysosomal enzyme degradation.
Exposure to laser light resulted in signiﬁcant cell toxicity
when the combination of ICG nanoparticles and saporin was
employed. In the presence of the ICGNP and d.ICGNP sys-
tems mean cell toxicity was increased to 52% and 45%,
respectively. Comparison of these results with those in
ﬁgure 5(b), where cells were irradiated in the presence of the
ICG-containing nanoparticles, leads to the conclusion that
even though a large proportion of cell toxicity in targets
treated with saporin is attributed to the photo-induced toxicity
of ICG-nanoparticles, a synergistic effect was observed with
combined treatment. More speciﬁcally, in the case of the
ICGNP, mean cell viability with light exposure was 63% and
48% in the absence and the presence of saporin, respectively.
Taking into consideration the 4% toxicity caused by saporin
alone under light irradiation, a synergistic effect of 11% in
cell toxicity was found. From a similar perspective, the results
did not demonstrate that there was a synergistic effect in the
case of the d.ICGNP formulation suggesting that the intact
nanoparticles are playing some role in enhancing the toxicity
of saporin.
The synergistic effect of ICGNP and saporin on toxicity
with laser light exposure was attributed to the photo-induced
drug internalization effect of the nanoparticles. In order to
further investigate this hypothesis, rhodamine-dextran was
employed as a surrogate for saporin in order to examine the
inﬂuence of the ICGNPs on its intracellular localization/
distribution using ﬂuorescence microscopy. SCC-9 cells were
co-incubated with rhodamine-dextran, in the presence or the
absence of ICGNP for 24 h. Cells were washed, treated with
laser light at the conditions described above and stained with
LysoTracker® Green. Figure 6 illustrates the photo-induced
effect of the ICGNP on lysosomal release of rhodamine-
dextran. In the absence of ICG-nanoparticles (panel A) the
ﬂuorescence of LysoTracker and rhodamine-dextran were co-
localized, implying that the latter was mainly localized in the
endo/lysosomal compartments. After laser irradiation in the
presence of ICGNP and d.ICGNP (panels B and C), rhoda-
mine-dextran appeared to disperse throughout the cytosol
when compared with the green ﬂuorescence emanated from
stained endo/lysosomes. Image analysis for red (rhodamine)
pixels along representative cytoplasmic regions demonstrated
that in the systems irradiated in the absence of nanoparticles,
the lysosomal localization of rhodamine-dextran in the cyto-
plasm is demonstrated by isolated peaks in ﬁgure 7(b), while
the systems treated in the presence of ICGNP and d.ICGNP
display dense peak proﬁles that demonstrate diffused cyto-
plasmic distribution of rhodamine. These observations
demonstrated the successful ICGNP-mediated, photo-induced
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endo/lysosomal escape of rhodamine-dextran and its diffu-
sion in the cytosol. Previous reports have demonstrated
photothermally-induced toxicity and endo/lysosomal escape
of drugs using graphene oxide,or non-biodegradable iron
oxide and silver nanoparticles [15, 48–50]. In the current
study, a biodegradable, tumour-responsive formulation has
been developed that, at sub-lethal concentrations and under
signiﬁcantly lower irradiation energy densities, offers a
similar attribute demonstrated by the induction of cellular
internalization and endo/lysosomal release of large mole-
cules. In the absence of the photo-induced internalization
effect elicited here by NIR in combination with the ICGNPs,
saporin is ineffective because its target is intracellular and, as
mentioned, it is membrane impermeable. Saporin molecules
that would be internalized into the cell would gain access by
an endocytotic route and remain within the endo/lysosomes
until eradicated within those vesicles by proteolysis. The
aspect of synergistically enhancing chemotherapy, in combi-
nation with the proto-induced cytotoxic effect of the for-
mulation, reveals the dual effect of the latter in NIR-based
tumour treatment and signiﬁes its potential applicability for
the management of head and neck or other superﬁcial cancers.
ICG has previously been described as a trifunctional
agent for photothermal therapy, as photothermal agent for
hyperthermia-triggered drug release and for optical imaging.
In a similar study, ICG-containing nano-liposomes were
developed for intratumoral release of doxorubicin with laser
light at 808 nm [16]. When irradiated with light of energy that
was more than three-fold higher than the energy provided in
the current treatment, the system exhibited synergistic cyto-
toxic effects only at elevated doxorubicin concentrations,
where dark toxicity was higher than 70%. For the system
developed in this study, dark toxicity did not exceed 25%,
even in the presence of saporin. Low dark toxicity is
Figure 6. NIR laser-induced release of rhodamine-dextran in SCC-9 cells: (a) ﬂuorescence images of cells in the absence of ICG-containing
nanoparticles (No NP) (panel A), the presence of ICGNP (panel B) and the presence of d.ICGNP (panel C). Systems were irradiated with
NIR at 805 nm, 150 mW cm−2, for 5 min Endo/lysosomes were stained with green Lysotracker (left panels) and red was the ﬂuorescence of
rhodamine-dextran (right panels). (b) Image analysis for red (rhodamine) pixels along linear selection (yellow line) of representative
cytoplasmic regions.
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particularly important for the clinical translation of a photo-
thermal ablative approach, in order to avoid post-treatment,
off-target cytotoxic effects and skin irritation.
The amphiphilic nature of ICG makes it suitable for
sensitizing endo/lysosomal membranes. For membrane sen-
sitization, release of free ICG from the PGA-based formula-
tion can occur in the tumour extracellular environment by the
action of cell-excreted cathepsin B or inside the lysosome by
the action of lysosomal cathepsin B (ﬁgure 7). Extracellular
ICG release can result in sensitization of the lysosome fol-
lowing its fusion with the endosome, which is part of the
cytoplasmic membrane that carries ICG. Nanoparticle
degradation inside the lysosome releases ICG that can directly
sensitize the lysosomal membrane. In the case of PCI treat-
ment for enhancing chemotherapy, it has been suggested that
sensitizer-induced lysosomal rupture upon light irradiation
results from free radical-mediated lipid peroxidation and
subsequent membrane destabilization [51]. As an NIR ﬂuor-
ophore, ICG has signiﬁcantly lower quantum yield (approx.
4.3% quantum yield at the emission wavelength of 805 nm)
than organic molecules with shorter emission wavelengths in
the visible region of the electromagnetic spectrum [52].
Despite the latter, it has previously been demonstrated that
excitation of ICG with light at 805 nm can cause a Type II
photodynamic reaction resulting in the generation of singlet
oxygen and the subsequent generation of lipid peroxides
followed by cell death [20]. Wan et al showed that low
concentrations of ICG (<2 μg ml−1) can deliver a weak
photo-induced hyperthermic effect [25]. They suggested that
the synergistic cytotoxicity induced by ICG at these low
concentrations, when used together with doxorubicin co-
harboured in micelles, is unlikely to have originated from
hyperthermia. Instead, it was hypothesized that the synergistic
cytotoxicity was correlated with the generation of intracellular
singlet oxygen from the amphiphilic ICG, which triggered the
disruption of the lysosomal membranes via a PCI effect
(ﬁgure 7), and subsequently induced enhanced susceptibility
of cancer cells to the chemotherapeutic agent [51].
4. Conclusion
Here, a formulation with dual responsiveness to both a
tumour-speciﬁc and an external stimulus was developed and
characterized. The nanoparticulate nature of the formulation
has the potential to facilitate improved tumour-accumulation
capability of an otherwise poorly-biodistributed photothermal
agent. Incubation with cathepsin B decreased nanoparticle
size and contributed to time-dependent ICG release. The
results clearly demonstrated that nanoparticle degradation by
cathepsin B can further increase cellular uptake and sub-
sequent photo-induced toxicity under NIR laser irradiation.
The formulation used in this study exhibited a photo-induced
drug internalization effect, when it was tested in combination
with the otherwise cell membrane-impermeable saporin.
Saporin contributed to increased cytotoxicity of this treatment
approach in a synergistic manner using the ICG-containing
nanoparticles. Fluorescence microscopy using rhodamine-
dextran as a saporin surrogate suggested that the synergistic
effect was due to photo-induced drug internalization follow-
ing sensitization and light-induced disruption of the endo/
lysosomal membrane in the presence of the ICG-containing
nanoparticles.
The main objectives of this study were to establish the
properties of the PGA-based formulation containing an NIR-
based agent, investigate its response to light irradiation and
Figure 7. (a) Endo-lysosomal membrane sensitization with ICG released from enzymatic digestion of nanoparticles, and (b) NIR laser-
induced endo/lysosome disruption and subsequent escape of the endocytosed saporin.
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cathepsin B, and correlate this response to subsequent cell
cytotoxicity. The treatment based on the ICG-containing
formulation described here has been designed to be used in
combination with any cytotoxic agent, particularly large
biomolecules such as saporin or membrane impermeable
chemotherapeutic agents such as bleomycin that can only
enter cells via endocytosis and may be susceptible to deacti-
vation by lysosomal enzymes and acidic pH. It is reasonable
to anticipate that the performance of the combined treatment
proposed here can be improved by co-harbouring the cyto-
toxic agent and ICG in the PGA-based nanoparticles.
Importantly, future studies that will focus on the drug-inter-
nalization aspect of the formulation, will employ PGA-
nanoparticles that co-harbour the photoresponsive and cyto-
toxic agents. Future studies will also aim to characterize the
performance of the proposed formulation in experimental
animal models for the treatment of orthotopic head and neck
tumours. Aspects, such as tumour accumulation, pharmaco-
kinetic proﬁles, diffusion throughout the tumour mass, pho-
tothermal antitumour efﬁcacy, the potential to enhance
chemotherapy and the level of spatial control of the treatment
itself, will be examined. In addition, considering the clinically
established acceptability of ICG as an imaging agent, the
diagnostic role of the proposed formulation will also be
evaluated for simultaneous tumour delineation, as a reporter
of payload release/nanoparticle degradation and precise
locoregional deposition. This diagnostic feature will further
emphasize the multifunctional potential of the formulation
described here in cancer therapy.
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